Form D: Unity Biotechnology $128.28 million Financing. Keith Leonard Submitted Dec 1 SEC form

Biotechnology Unity Biotechnology, Inc. - Keith Leonard

Unity Biotechnology Financing

Unity Biotechnology, Inc., Corporation just submitted form D for $128.28 million equity financing. This is a new filing. Unity Biotechnology was able to sell $108.32 million. That is 84.44% of the financing offer. The total financing amount was $128.28 million. The fundraising form was filed on 2016-12-01. The reason for the financing was: unspecified. The fundraising still has about $19.96 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Unity Biotechnology is based in California. The firm’s business is Biotechnology. The form was submitted by Keith Leonard Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 3280 Bayshore Boulevard, Brisbane, Ca, California, 94005. Nathaniel E. David is the related person in the form and it has address: C/O Unity Biotechnology, Inc., 3280 Bayshore Boulevard, Brisbane, Ca, California, 94005. Link to Unity Biotechnology Filing: 000114036116088337.

Analysis of Unity Biotechnology Offering

On average, companies in the Biotechnology sector, sell 73.77% of the total offering amount. Unity Biotechnology sold 84.44% of the offering. The financing is still open. Could this mean that the trust in Unity Biotechnology is high? The average fundraising amount for companies in the Biotechnology industry is $3.08 million. The total amount raised is 3,416.89% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering is set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Unity Biotechnology Also

The Form D signed by Keith Leonard might help Unity Biotechnology, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment